Sign inJoin waitlistJoin the waitlist

Ranjana Advani

Lymphoma DMG Leader, Stanford Cancer Institute · Stanford Health Care

Credentials: · · ·

History

Stanford University Hematology and Oncology Fellowship (1996) CA
1993–1996
Stanford University
1987–1990
Internal Medicine
Santa Clara Valley Healthcare
1984–1987
Bombay University (1982) India
1978–1982

Research

The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Review · Blood · 2016 · 5,887 citations
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
New England Journal of Medicine · 2013 · 1,377 citations
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood · 2022 · 1,363 citations

Richard Hoppe
73 papers
Nancy Bartlett
58 papers
Leo Gordon
43 papers
Julie Vose
42 papers
SH
Steven Horwitz
42 papers
BK
Brad Kahl
35 papers
Sandra Horning
35 papers
Stephen Ansell
33 papers
Yasodha Natkunam
31 papers
AZ
Andrew Zelenetz
30 papers
Sonali Smith
29 papers
Joachim Yahalom
27 papers

Clinical trials

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Principal investigator · Terminated · Phase 2
Ranjana Advani
2022–2025
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Principal investigator · Recruiting
Associazione Angela Serra per la ricerca sul cancro
2018–2025
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Principal investigator · Completed · Phase 2
Stanford University
2001–2017
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Study chair · Terminated · Phase 2
ECOG-ACRIN Cancer Research Group
2013–2018